HKTDC
9.4.2024 10:55:30 CEST | Business Wire | Press release
Hong Kong Trade Development Council:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408808037/en/
HKTDC Hong Kong Gifts & Premium Fair, Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong will be held on 27-30 April (Photo: Business Wire)
HKTDC Hong Kong Gifts & Premium Fair
Featuring a curated selection of gift and premium products from around 4000 exhibitors from 21 countries and regions, the fair will be held at the Hong Kong Convention and Exhibition Centre from 27-30 April, with the online matching services “Click2Match” available from 20 April to 7 May. It offers an ideal platform for exhibitors to showcase their latest products, and foster networking and collaboration among industry professionals.
The Hall of Fine Designs will return as a convergence of reputed global brands, including Red A (Hong Kong), Tiny Memory (Hong Kong), YASHICA (Japan) and more. The pavilion formed by Hong Kong Exporters' Association will showcase the design skills and branding excellence of local product designers. Winning works from the Hong Kong Smart Design Awards will also be displayed to highlight the creativity and flair of Hong Kong brands to global industry players.
The anticipated Cultural & Creative Corner will captivate visitors with its vibrant showcase of designer brands and products with unique styles. Catering to the latest trends, the brand-new Outdoor & Sporting Goods zone will showcase a series of products including camping gear, dance shoes, and sporting goods.
To keep visitors abreast of the latest market information and encourage networking, there will be seminars hosted by industry players and associations to share insights on areas crucial to the sector’s development such as consumer market trends, sustainability and silver economy.
Hong Kong International Printing & Packaging Fair & DeLuxe PrintPack Hong Kong
Jointly organised by the Hong Kong Trade Development Council and CIEC Exhibition Company (HK) Limited, the two printpack Fairs will be held from 27-30 April at AsiaWorld-Expo, with the online matching services “Click2Match” available from 20 April to 7 May.
The Printing & Packaging Fair is a premier marketplace to source printing and packaging equipment, products and services. As global demand for luxury packaging grows, the acclaimed World of DeLuxe PrintPack Zone at the Fair will spin off and launch as DeLuxe PrintPack Hong Kong this year. Together, the two Fairs will host around 500 exhibitors, offering a comprehensive showcase of industry-leading solutions.
Highlighted Zones:
- Green Printing & Packaging: bio-degradable materials, upcycled products and innovative green solutions
- Food & Beverage Packaging: functional solutions designed for fresh, chilled, and processed food
- E-commerce Packaging: creative solutions for enterprises to capture e-tailing opportunities
The debut DeLuxe PrintPack will present an array of printing and packaging solutions tailored for luxury goods including jewellery, watches, cosmetics, gourmet food, and wine.
Forums and networking activities will be held share industry trends, sustainable designs and the impact of deluxe packaging on brand identity. Award-winning entries from the Hong Kong Print Awards, the Hong Kong Digital Printing Award and the GAAHK x PolyU Design - Packaging Design will be presented to showcase innovations in printpack design and production.
Register Now: https://tinyurl.com/2jrph7z2
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408808037/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom